Endocrine resistance remains a key challenge in HR+/HER2- advanced breast cancer, particularly after progression on CDK4/6 inhibitors. The CAPItello-291 trial, published in The New England Journal of Medicine (2023), highlighted the role of capivasertib, an AKT inhibitor, in addressing this issue.
The study demonstrated that adding capivasertib to fulvestrant significantly improved progression-free survival (7.2 vs. 3.6 months), with even greater benefit in patients with PIK3CA, AKT1, or PTEN alterations (7.3 vs. 3.1 months). The treatment was generally well tolerated, with rash (12%) and diarrhea (9%) being the most notable adverse events.
As research continues to refine treatment strategies for HR+/HER2- breast cancer, targeted therapies like capivasertib remain an important focus in overcoming endocrine resistance.
For more information:https://lnkd.in/eR-ncJyg
